Dexmedetomidine Hydrochloride
Brand Names: Precedex
Methodology & AI Transparency ⓘ
Dexmedetomidine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a alpha 2 -adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting.
- 2 Real-world patient consensus: Tracked across 7 patient dosage logs with a 87% satisfaction benchmark (RxCUI 1718906).
- 3 Typical cash cost range: Public pharmacy ledger: $128.38 low cash benchmark vs. $314.53 chain retail average ($2.9600/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Dexmedetomidine Hydrochloride include dry mouth (8.2%), orthostatic hypotension (3.3%), nausea (8.4%).
Ask our AI Specialists anything about Dexmedetomidine Hydrochloride
Dexmedetomidine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a alpha 2 -adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride in 0.9% sodium chloride injection by continuous infusion not to exceed 24 hours. ( 1.1 ) Sedation of non-intubated adult patients prior to and/or during surgical and other procedures.
12.1 Mechanism of Action Dexmedetomidine is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10 to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration.
Systemic exposure to Dexmedetomidine Hydrochloride reflects Complete (~100%) parenteral systemic delivery for Dexmedetomidine Hydrochloride (4 ug/mL Injection, Solution) absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across dexmedetomidine hydrochloride regimens, sustaining receptor engagement across a 6 minutes terminal elimination (Dexmedetomidine Hydrochloride SPL) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after dexmedetomidine hydrochloride administration response profile).
Dosing protocols (4 ug/mL Injection, Solution or 100 ug/mL Injection, Solution or 200 ug/50mL Injection or 4 ug/mL Injection or 100 ug/mL Injection, Solution, Concentrate) balance efficacy (87.00% patient satisfaction across 7 logs) against nausea (8.4% of reports), dry mouth (8.2% of reports), headache (7% of reports), with strict avoidance in severe drug-induced hypersensitivity to dexmedetomidine hydrochloride or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2023-10-06 for dexmedetomidine hydrochloride.
Patients taking Dexmedetomidine Hydrochloride should avoid unmonitored CNS depressants due to compounded vigilance impairment.
Assess baseline hepatic panels and interacting prescriptions when starting Dexmedetomidine Hydrochloride (central alpha-2 adrenergic agonist).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Dexmedetomidine Hydrochloride or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2023-10-06 for Dexmedetomidine Hydrochloride
Logged Side-Effect Incidence (7 Reports)
Dexmedetomidine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dexmedetomidine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Calmer Recovery After Surgery: How This Sedative Steadies Breathing and Heart Rate Dexmedetomidine as an add-on booster to oxycodone PCA produced transient blood flow and heart rate effects without differences in slow heart rate or in the measured breathing variables. Acta anaesthesiologica Scandinavica • 2027-01-15 • Randomized Controlled Trial | N = 98 | 88/100 | PMID 42929478 ↗ |
| Calmer Recovery After Surgery: How This Sedative Steadies Breathing and Heart Rate Among 41 patients (median age, 62 years; median injury severity score, 20), no significant differences were found in baseline characteristics between groups. JAMA surgery • 2025-10-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40900569 ↗ |
| Calmer Recovery After Surgery: How This Sedative Steadies Breathing and Heart Rate Least squares mean differences (97.5% confidence intervals) in the sublingual dexmedetomidine groups were -5.5 (-6.7 to -4.3) for 180 μg and -3.7 (-4.9 to -2.5) for 120 μg (both P Conclusions: Treatment with sublingual... The Journal of clinical psychiatry • 2022-10-03 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36198061 ↗ |
| Faster Wake-Up After a Procedure: How a Newer Sedative Compares to Standard Anesthesia Remimazolam provides effective sedation for fiberoptic bronchoscopy with advantages in terms of breathing and blood flow and heart rate safety, rapid recovery, and procedural efficiency. Journal of bronchology & interventional pulmonology • 2027-01-01 • Meta-Analysis | Multi-cohort | 86/100 | PMID 42935012 ↗ |
| Calmer Recovery After Surgery: How This Sedative Steadies Breathing and Heart Rate CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations. BMC anesthesiology • 2026-02-27 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41761098 ↗ |
Dexmedetomidine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.9600/unit (~$88.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $314.53 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $128.38 / mo | View logs ↓ |
Dexmedetomidine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dexmedetomidine Hydrochloride RxNorm Concept ID | 1718906 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.9600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $314.53 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $128.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dexmedetomidine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Dexmedetomidine Hydrochloride: FDA labeling (2023-10-06, NDC 25021-615), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dexmedetomidine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.